Ironwood Pharmaceuticals Stock Net Income
| IRWD Stock | USD 8.28 0.06 0.73% |
Ironwood Pharmaceuticals fundamentals help investors to digest information that contributes to Ironwood Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Ironwood Stock. The fundamental analysis module provides a way to measure Ironwood Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ironwood Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -1 B | -952.1 M | |
| Net Loss | -980.9 M | -931.9 M | |
| Net Income Applicable To Common Shares | 201.3 M | 211.4 M | |
| Net Loss | (6.45) | (6.13) | |
| Net Income Per E B T | 1.06 | 0.79 |
Ironwood | Net Income |
Ironwood Pharmaceuticals Company Net Income Analysis
Ironwood Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Ironwood Pharmaceuticals Net Income | (1 B) |
Most of Ironwood Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ironwood Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Ironwood Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Ironwood Pharmaceuticals is extremely important. It helps to project a fair market value of Ironwood Stock properly, considering its historical fundamentals such as Net Income. Since Ironwood Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ironwood Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ironwood Pharmaceuticals' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Ironwood Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Ironwood Pharmaceuticals reported net income of (1 Billion). This is 393.67% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is significantly higher than that of the company.
Ironwood Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ironwood Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ironwood Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ironwood Pharmaceuticals by comparing valuation metrics of similar companies.Ironwood Pharmaceuticals is currently under evaluation in net income category among related companies.
Ironwood Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Ironwood Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ironwood Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ironwood Pharmaceuticals' value.| Shares | Geode Capital Management, Llc | 2023-12-31 | 3.1 M | Jacobs Levy Equity Management, Inc. | 2023-09-30 | 2.4 M | Jupiter Asset Management Limited | 2023-12-31 | 2.3 M | Goldman Sachs Group Inc | 2023-12-31 | 2.2 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 2.1 M | Nuveen Asset Management, Llc | 2023-12-31 | 1.8 M | Northern Trust Corp | 2023-12-31 | 1.6 M | Driehaus Capital Management Llc | 2023-12-31 | 1.6 M | Adage Capital Partners Gp Llc | 2023-12-31 | 1.5 M | Blackrock Inc | 2023-12-31 | 26 M | Sarissa Capital Management Lp | 2023-09-30 | 16.4 M |
Ironwood Fundamentals
| Return On Equity | -6.74 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | (2.26) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 1.84 B | ||||
| Shares Outstanding | 158.96 M | ||||
| Shares Owned By Insiders | 1.73 % | ||||
| Shares Owned By Institutions | 98.27 % | ||||
| Number Of Shares Shorted | 21.16 M | ||||
| Price To Earning | 18.35 X | ||||
| Price To Book | 2.59 X | ||||
| Price To Sales | 2.79 X | ||||
| Revenue | 442.74 M | ||||
| Gross Profit | 366.33 M | ||||
| EBITDA | 210.61 M | ||||
| Net Income | (1 B) | ||||
| Cash And Equivalents | 504.36 M | ||||
| Cash Per Share | 3.29 X | ||||
| Total Debt | 715.54 M | ||||
| Debt To Equity | 0.78 % | ||||
| Current Ratio | 26.52 X | ||||
| Book Value Per Share | (2.21) X | ||||
| Cash Flow From Operations | 183.43 M | ||||
| Short Ratio | 5.44 X | ||||
| Earnings Per Share | (6.45) X | ||||
| Price To Earnings To Growth | (0.26) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 267 | ||||
| Beta | 0.55 | ||||
| Market Capitalization | 1.23 B | ||||
| Total Asset | 471.07 M | ||||
| Retained Earnings | (1.7 B) | ||||
| Working Capital | (42.81 M) | ||||
| Current Asset | 500.2 M | ||||
| Current Liabilities | 76.47 M | ||||
| Net Asset | 471.07 M |
About Ironwood Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ironwood Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ironwood Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ironwood Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Ironwood Pharmaceuticals Piotroski F Score and Ironwood Pharmaceuticals Altman Z Score analysis. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Ironwood Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.69) | Earnings Share (6.45) | Revenue Per Share 2.848 | Quarterly Revenue Growth 0.097 | Return On Assets 0.1339 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.